Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Soligenix Inc (SNGX)

Soligenix Inc (SNGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,406
  • Shares Outstanding, K 10,086
  • Annual Sales, $ 120 K
  • Annual Income, $ -8,270 K
  • EBIT $ -12 M
  • EBITDA $ -12 M
  • 60-Month Beta 1.99
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.60

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0526 +16.85%
on 02/17/26
1.2891 -4.58%
on 03/13/26
+0.1400 (+12.84%)
since 02/13/26
3-Month
1.0200 +20.59%
on 02/05/26
1.4900 -17.45%
on 01/05/26
-0.2900 (-19.08%)
since 12/16/25
52-Week
1.0200 +20.59%
on 02/05/26
6.2299 -80.26%
on 08/18/25
-1.0700 (-46.52%)
since 03/14/25

Most Recent Stories

More News
Soligenix (NASDAQ: SNGX) SGX945 Granted Promising Innovative Medicine Designation in UK for Behçet Disease

Soligenix (NASDAQ: SNGX) announced that SGX945 (dusquetide) has received Promising Innovative Medicine (“PIM”) designation from the U.K. Medicines and Healthcare Products Regulatory Agency for the...

SNGX : 1.2300 (unch)
Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency

PRINCETON, N.J. , March 10, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...

SNGX : 1.2300 (unch)
Soligenix (NASDAQ: SNGX) Leverages Platform Science for Broader Therapeutic Reach

Modern biopharmaceutical innovation often revolves around a powerful idea: One scientific mechanism can unlock treatments for multiple diseases. Rather than building entirely new molecules for every indication,...

SNGX : 1.2300 (unch)
Soligenix (NASDAQ: SNGX) Receives Positive EMA Orphan Drug Opinion for Dusquetide in Behçet Disease

Soligenix (NASDAQ: SNGX) announced that the European Medicines Agency Committee for Orphan Medicinal Products issued a positive recommendation for orphan drug designation of dusquetide, the active ingredient...

SNGX : 1.2300 (unch)
Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease

PRINCETON, N.J. , Feb. 26, 2026 /PRNewswire/ -- Soligenix, Inc.  (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...

SNGX : 1.2300 (unch)
Soligenix (NASDAQ: SNGX) CEO to Present at BIO Investment & Growth Summit

Soligenix (NASDAQ: SNGX) announced that Christopher J. Schaber, Ph.D., president and chief executive officer, will deliver a corporate presentation at the BIO Investment & Growth Summit at 3 p.m. on March...

SNGX : 1.2300 (unch)
Soligenix to Present at BIO Investment & Growth Summit

PRINCETON, N.J. , Feb. 24, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...

SNGX : 1.2300 (unch)
Soligenix (NASDAQ: SNGX) CEO Highlights 2026 Clinical Milestones and Strategic Options

Soligenix (NASDAQ: SNGX) issued a shareholder update from President and CEO Dr. Christopher J. Schaber outlining anticipated 2026 milestones across its late-stage rare disease pipeline, including top-line...

SNGX : 1.2300 (unch)
Soligenix Details Recent Progress and Upcoming Milestones

PRINCETON, N.J. , Feb. 12, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...

SNGX : 1.2300 (unch)
Soligenix (NASDAQ: SNGX) Driving Innovation in Photodynamic Therapy Potential in Oncology, Dermatology

From lab research to clinical application, photodynamic therapy (“PDT”) is emerging as a powerful treatment approach that uses light and chemistry to selectively target diseased tissue. As this modality...

SNGX : 1.2300 (unch)
BMWYY : 29.2000 (+4.58%)

Business Summary

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases where, as well as developing several biodefense vaccines and therapeutics. The Company operates in two reportable...

See More

Key Turning Points

3rd Resistance Point 1.3365
2nd Resistance Point 1.3032
1st Resistance Point 1.2666
Last Price 1.2300
1st Support Level 1.1967
2nd Support Level 1.1634
3rd Support Level 1.1268

See More

52-Week High 6.2299
Fibonacci 61.8% 4.2397
Fibonacci 50% 3.6249
Fibonacci 38.2% 3.0102
Last Price 1.2300
52-Week Low 1.0200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar